Moderna, Inc.

Moderna, Inc. develops and commercializes mRNA medicines, with its current business centered on respiratory vaccines. The company sells COVID-19 and RSV vaccines through a global commercial network and also earns other revenue from government, collaboration, licensing, and manufacturing-readiness agreements.

−147,3 %

55,3 %

−145,2 %

−39,9 %

3.29

3.22

— Moderna, Inc.
	%
Commercial vaccines	92% Approved respiratory vaccines sold in the commercial market and to governments.
Other revenue	8% Grant, collaboration, licensing, royalty, and stand-ready manufacturing revenue.

Moderna sells primarily to wholesalers, distributors, retailers, healthcare providers, foreign governments, and...

U.S. commercial vaccine channelprimary
Wholesalers, distributors, retailers, and providers buy seasonal COVID and RSV vaccines for patient use.
Foreign governments and public buyersprimary
National health authorities and international organizations buy vaccine supply and capacity commitments.
Strategic collaboratorssecondary
Partners such as Merck, Vertex, BARDA, DARPA, and the Gates Foundation fund or co-develop programs.
Healthcare decision makersprimary
Physicians, payors, and public health bodies influence uptake through recommendations and reimbursement.

Moderna operates a commercial footprint across North America, Europe, and Asia-Pacific, with the U.S...

•North America is the core commercial market, especially the United States
•Europe is served through local subsidiaries and distributor relationships
•Asia-Pacific is part of the company’s expanding commercial footprint
•UK, Canada, and Australia host licensed mRNA manufacturing facilities
•Government purchase commitments support regional manufacturing economics

Moderna is building a commercial model around respiratory vaccines while expanding its mRNA pipeline and manufacturing...

Grow the respiratory vaccine portfolioshort-term

Current revenue depends heavily on Spikevax, mNEXSPIKE, and mRESVIA.

Expand global commercial and manufacturing footprintmedium-term

Local presence and regional supply improve access, execution, and resilience.

Scale the mRNA pipeline with digital and AI toolslong-term

Pipeline breadth is needed to reduce dependence on seasonal vaccines.

Moderna’s business is exposed to regulatory shifts, vaccine demand volatility, and intense competition from larger...

high

Regulatory and public health guidance changes

FDA, CDC, and ACIP decisions can change vaccine eligibility and demand.

Scope: Approved vaccines and future launches
Materiality: high

high

Competitive pressure in COVID and RSV vaccines

Larger rivals can bundle products, leverage scale, and win contracts.

Scope: Spikevax, mNEXSPIKE, and mRESVIA
Materiality: high

high

Manufacturing and cybersecurity disruption

Highly automated, digitally integrated facilities can fail or be attacked.

Scope: Owned and third-party manufacturing network
Materiality: high

high

Variable consideration and returns

Chargebacks, rebates, and returns can significantly reduce net product sales.

Scope: U.S. private vaccine market and foreign markets
Materiality: high

medium

Seasonality and demand volatility

Respiratory vaccine orders vary by season, viral evolution, and consumer uptake.

Scope: Commercial vaccine sales
Materiality: high

Variable consideration on vaccine sales

Directly affects net product sales and gross margin

Deferred revenue from supply agreements

Creates timing differences between cash flow and revenue

Other revenue recognition

Can shift reported revenue mix and period comparability

Estimates for product returns

Can materially change reported revenue and reserves

Moderna, Inc.

Regulatory and public health guidance changes

Competitive pressure in COVID and RSV vaccines

Manufacturing and cybersecurity disruption

Variable consideration and returns

Seasonality and demand volatility

PFIZER INC

NOVAVAX INC

Merck & Co., Inc.

Vaxcyte, Inc.

TEVA PHARMACEUTICAL INDUSTRIES LTD

MOLINA HEALTHCARE, INC.